Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12348258 | 1.00 | MAPK1 (0.51) | MAPK1HPGDTSHRF10LMNA | |
| SCHEMBL469776 | 1.00 | MAPK1 (0.51) | MAPK1HPGDTSHRF10LMNA | |
| SCHEMBL1136065 | 0.86 | MAPK1 (0.52) | MAPK1HPGDTSHRF10LMNA | |
| SCHEMBL16416468 | 0.86 | MAPK1 (0.52) | MAPK1HPGDTSHRF10LMNA | |
| SCHEMBL1136066 | 0.86 | MAPK1 (0.52) | MAPK1HPGDTSHRF10LMNA | |
| SCHEMBL15221118 | 0.86 | MAPK1 (0.52) | MAPK1HPGDTSHRF10LMNA | |
| SCHEMBL14830273 | 0.86 | MAPK1 (0.52) | MAPK1HPGDTSHRF10LMNA | |
| SCHEMBL14838637 | 0.85 | MAPK1 (0.51) | MAPK1HPGDTSHRF10LMNA | |
| SCHEMBL78371 | 0.85 | MAPK1 (0.51) | MAPK1HPGDTSHRF10LMNA | |
| SCHEMBL28025617 | 0.85 | MAPK1 (0.51) | MAPK1HPGDTSHRF10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106192-B2 | Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-31 | — | — | US | claimed |
| US-20100081807-A1 | METHOD FOR PRODUCING 5-CLORO-N-(METHYL)-2-THIOPHENECARBOXAMIDE | BAYER HEALTHCARE AG (DE) | 2010-04-01 | — | — | US | claimed |
| US-20070149522-A1 | Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide | BAYER HEALTHCARE AG (DE) | 2007-06-28 | — | — | US | claimed |
| US-20250066340-A1 | METHOD FOR SYNTHESIZING RIVAROXABAN | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4434983-A1 | METHOD FOR SYNTHESIZING RIVAROXABAN | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2024-09-25 | — | — | EP | disclosed |
| CN-118176191-A | Synthesis method of rivaroxaban | 浙江华海药业股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2023088229-A1 | METHOD FOR SYNTHESIZING RIVAROXABAN | 浙江华海药业股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2023088229-A1 | METHOD FOR SYNTHESIZING RIVAROXABAN | 浙江华海药业股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| EP-2705028-B1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2019-08-21 | — | — | EP | disclosed |
| US-20170267669-A1 | Process for the Preparation of Rivaroxaban | CIPLA LIMITED (IN) | 2017-09-21 | — | — | US | disclosed |
| EP-3186246-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN | Cipla Limited (IN) | 2017-07-05 | — | — | EP | disclosed |
| US-7351823-B2 | Preparation process | BAYER HEALTHCARE AG (DE) | 2008-04-01 | — | — | US | disclosed |
| US-20070149522-A1 | Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide | BAYER HEALTHCARE AG (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149522-A1 | Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide | BAYER HEALTHCARE AG (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070066615-A1 | Heterocyclic compounds | BAYER HEATHCARE AG (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066615-A1 | Heterocyclic compounds | BAYER HEATHCARE AG (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066615-A1 | Heterocyclic compounds | BAYER HEATHCARE AG (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1626969-A1 | HETEROCYCLIC COMPOUNDS | Bayer HealthCare AG (DE) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004101557-A1 | HETEROCYCLIC COMPOUNDS | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004060887-A1 | METHOD FOR PRODUCING 5-CHLORO-N-({5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)-PHENYL]-1,3-OXAZOLIDIN-5-YL}-METHYL)-2-THIOPHENE CARBOXAMIDE | BAYER HEALTHCARE AG (DE) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066340-A1 | METHOD FOR SYNTHESIZING RIVAROXABAN | F2, VKORC1, F12 | MAPK1 2089/4885HPGD 337/4885TSHR 857/4885 |
| US-20070149522-A1 | Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide | NT5C, NOX5, MT-ND5 | MAPK1 4432/4885HPGD 1313/4885TSHR 2837/4885 |
| US-20100081807-A1 | METHOD FOR PRODUCING 5-CLORO-N-(METHYL)-2-THIOPHENECARBOXAMIDE | CBR3, NT5C, CBR1 | MAPK1 4781/4885HPGD 885/4885TSHR 2510/4885 |
| US-20170267669-A1 | Process for the Preparation of Rivaroxaban | F7, F5, F2 | MAPK1 2591/4885HPGD 608/4885TSHR 3124/4885 |
| US-20070066615-A1 | Heterocyclic compounds | F2, SERPINC1, TFPI | MAPK1 3699/4885HPGD 25/4885TSHR 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.